GUTS Key Statistics, Chart & Performance
The current stock price of GUTS is 1.97 USD. In the past month the price decreased by -15.91%. In the past year, price decreased by -11.48%.
GUTS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to GUTS. When comparing the yearly performance of all stocks, GUTS is one of the better performing stocks in the market, outperforming 72.6% of all stocks.
GUTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GUTS. Both the profitability and financial health of GUTS have multiple concerns.
GUTS Financial Highlights
Over the last trailing twelve months GUTS reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS decreased by -59.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -106.94% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GUTS Forecast & Estimates
11 analysts have analysed GUTS and the average price target is 7.18 USD. This implies a price increase of 264.51% is expected in the next year compared to the current price of 1.97.
For the next year, analysts expect an EPS growth of -8.53% and a revenue growth -100% for GUTS
GUTS Ownership
About GUTS
Company Profile
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
Company Info
FRACTYL HEALTH INC
3 Van De Graaff Drive, Suite 200
Burlington MASSACHUSETTS US
Employees: 107
Phone: 17819028800
FRACTYL HEALTH INC / GUTS FAQ
What does GUTS do?
Fractyl Health, Inc. is a metabolic therapeutics company. The company is headquartered in Burlington, Massachusetts and currently employs 107 full-time employees. The company went IPO on 2024-02-02. The firm is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
What is the current price of GUTS stock?
The current stock price of GUTS is 1.97 USD. The price increased by 6.49% in the last trading session.
Does GUTS stock pay dividends?
GUTS does not pay a dividend.
What is the ChartMill technical and fundamental rating of GUTS stock?
GUTS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for GUTS stock?
11 analysts have analysed GUTS and the average price target is 7.18 USD. This implies a price increase of 264.51% is expected in the next year compared to the current price of 1.97.
Can you provide the ownership details for GUTS stock?
You can find the ownership structure of FRACTYL HEALTH INC (GUTS) on the Ownership tab.